NEW YORK (GenomeWeb) – A team of researchers from Pfizer, the University of Glasgow, and Oxford BioDynamics have developed a new method to discern who will respond poorly to methotrexate, a drug sold by Pfizer that is commonly used to treat people with onset rheumatoid arthritis.

The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

York University researchers find genomic evidence of inbreeding in the yellow-banded bumblebee, according to Reuters.

In its survey of US adults, the Pew Research Center finds that views on the genetic engineering of animals depend on why it's done.

The Scientist reports agricultural researchers are working on a gene-stacking tool.

In Nature this week: statistical method for overcoming case-control imbalance issues, and more.